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SUMMARY – One of the drugs that are widely used in the treatment of atrial fibrillation is 
amiodarone. Despite considerable prolongation of the corrected QT interval and a substantial degree 
of bradycardia, amiodarone exhibits a remarkably low frequency of pro-arrhythmic events and <1.0% 
incidence of torsades de pointes, mostly after long-term usage. We present a case of an 80-year-old 
female with paroxysmal atrial fibrillation accompanied by acute heart failure treated by short-term 
parenteral amiodarone therapy and development of torsades de pointes.
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Introduction
Atrial fibrillation is one of the most common ar-
rhythmias in daily clinical practice, associated with a 
significant risk of stroke, congestive heart failure, and 
higher mortality rate1. One of the drugs that are wide-
ly used in treating atrial fibrillation is amiodarone. 
Amiodarone is a unique antiarrhythmic agent of a 
‘wide-spectrum’, primarily of class III activity (pro-
longs phase 3 of the cardiac action potential, the repo-
larization phase where there is normally decreased cal-
cium permeability and increased potassium permea-
bility)2. Besides efficacy in the treatment of patients 
with atrial fibrillation and ventricular arrhythmias, 
treatment with amiodarone is associated with numer-
ous possible side effects. Despite considerable prolon-
gation of the corrected QT interval (QTc) and a sub-
stantial degree of bradycardia, amiodarone exhibits a 
remarkably low frequency of pro-arrhythmic events 
and <1.0% incidence of torsades de pointes, mostly af-
ter long-term usage3,4. Torsades de pointes is a life-
threatening arrhythmia associated with prolongation 
of the QTc interval on electrocardiogram (ECG). The 
treatment of hemodynamically stable torsades de 
pointes involves discontinuation of the offending 
drug(s), correction of electrolyte abnormalities and ad-
ministration of intravenous magnesium sulfate5.
We present a case of an 80-year-old female with 
paroxysmal atrial fibrillation accompanied by acute 
heart failure treated by short-term parenteral amioda-
rone therapy and development of torsades de pointes.
Case Report
An 80-year-old female was admitted to the Inten-
sive Care Unit (ICU) of our hospital due to paroxys-
mal atrial fibrillation with rapid ventricular response 
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Fig. 1. Paroxysmal atrial fibrillation at admission.
Fig. 2. Torsades de pointes during short-term amiodarone treatment.
(Fig. 1) accompanied by acute heart failure. Arterial 
hypertension had been present for one year but the pa-
tient failed to take the recommended antihypertension 
therapy on regular basis (lacidipine 4 mg). In the last 
two weeks prior to admission to the hospital, the pa-
tient started noticing progressive effort intolerance ac-
companied by dyspnea. Upon her admission to the 
hospital, the signs of acute heart failure were found 
clinically and radiologically, along with newly diag-
nosed atrial fibrillation with ventricular tachyarrhyth-
mia up to 200/min.
Laboratory results showed mild macrocytic anemia 
(hemoglobin (Hb) 115 g/L; mean corpuscular volume 
(MCV) 108), chronic renal insufficiency (urea 11.1 
mmol/L; creatinine 171 µmol/L; creatinine clearance 
(Cockcroft-Gault equation) 30.2 mL/min) and mild 
hypokalemia (3.7 mmol/L). ECG did not show sig-
nificant ST-T changes (high-sensitivity troponin I 
(hs-troponin I) 56.1 ng/L. Treatment with enoxapa- 
rin 60 mg s.c., furosemide 40 mg i.v., potassium sub-
stitution and amiodarone infusion was initiated at 
Emergency Room (ER), then the patient was trans-
ferred to the ICU where amiodarone infusion was 
continued.
Shortly after therapy had been initiated, ventricular 
frequency slowed down significantly to <100 /min, 
with regression of the patient’s subjective symptoms. 
Approximately six hours after initiating the adminis-
tration of amiodarone, the patient experienced tors-
ades de pointes paroxysms lasting for up to 10 seconds 
(Fig. 2). Both paroxysms were noted at night while the 
patient was asleep. The paroxysms ceased spontane-
ously, hence there was no need for resuscitation or 
electrical cardioversion. After that, the i.v. amiodarone 
infusion was terminated, the magnesium and potassi-
um concentrations were measured and proved to be 
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lowered (Mg 0.49 mmol/L, K 3.5 mmol/L), and sig-
nificant QTc prolongation up to 569 ms was found on 
the new ECG recording (Fig. 3) with wide, biphasic to 
negative T waves in inferior and V3-V6 leads and un-
stable sinus rhythm with supraventricular and ventric-
ular ectopic beats. Shortly after that, the patient expe-
rienced another torsades de pointes paroxysm with 
repeated spontaneous conversion into sinus rhythm 
without losing her consciousness. Magnesium sulfate 
was immediately introduced into therapy at a dosage 
of 9 mmol (2.25 g) i.v. bolus, which was followed by 
continuous magnesium infusion alongside potassium 
substitution and bisoprolol at a dosage of 1.25 mg. 
Clinically, the patient no longer experienced signifi-
cant dyspnea or chest pain and laboratory results 
showed no dynamics that would indicate acute coro-
nary syndrome (follow up hs-troponin I 50.3, 36.6 
ng/L). The ECHO-cardiogram showed mild to mod-
erate mitral regurgitation, left atrium of borderline di-
ameter (4.0 cm), angio 2+ tricuspid regurgitation with 
estimated pressure in the right ventricle up to 40 mm 
Hg, non-dilated (LVIDd 4.5 cm) and non-hypertro-
phic left ventricle with left ventricular ejection fraction 
(EFLV) 45%-50%, without clear segmental kinetic 
abnormalities (2D). After amiodarone therapy had 
been discontinued and electrolyte imbalance corrected 
(Mg 1.29, 0.97 mmol/L), there were no torsades de 
pointes attacks. Within the next few days, the patient’s 
condition gradually stabilized, there were no signs of 
acute heart failure, and sinus rhythm stabilized with 
rare short-term paroxysms of atrial fibrillation. Medi-
cal therapy was optimized, warfarin was introduced. 
The QTc interval gradually decreased to 447 ms and T 
wave positivity (Fig. 4) was followed by serial ECG 
recording two weeks after admission to the hospital 
and amiodarone introduction. The patient was dis-
charged in a stable condition with the following ther-
apy: warfarin 1.5 mg, ramipril/amlodipine 5/5 mg, 
furosemide 40 mg, eplerenone 50 mg and bisoprolol 
1.25 mg.
Discussion
Although it is well known that different drugs can 
lead to significant prolongation of the QTc interval 
and subsequent torsades de pointes phenomena, the 
case presented is relatively rare since it occurred after a 
very short amiodarone administration, i.e. already 6 
hours after the medication had been administered. 
There are literature data on QTc prolongation and the 
incidence of torsades de pointes after long-term6,7, as 
well as short-term drug administration, 4-5 days from 
treatment initiation3.
The known risk factors for torsades de pointes in-
clude QTc interval >500 ms, QTc interval increase by 
≥60 ms from the pretreatment value, advanced age, fe-
Fig. 3. Significant QTc prolongation (569 ms).
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Fig. 4. ECG at discharge (QTc 447 ms).
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male sex, acute myocardial infarction, heart failure 
with reduced ejection fraction, hypokalemia, hypo-
magnesemia, hypocalcemia, bradycardia, treatment 
with diuretics and elevated plasma concentrations of 
QTc interval-prolonging drugs due to drug interac-
tions, inappropriate dose adjustment of kidney elimi-
nated drugs in patients with kidney disease and rapid 
intravenous administration8,9.
Besides amiodarone therapy, there were several 
predisposing factors for the occurrence of torsades de 
pointes in our patient, including age, gender, moderate 
renal failure, hypomagnesemia and hypokalemia in the 
acute phase and QTc interval at the upper limit of the 
normal value.
Drug-induced excessive QT prolongation most 
commonly occurs in patients with subclinical muta-
tions in one of the genes responsible for the congenital 
long QT syndrome10. These patients are susceptible to 
developing torsades de pointes if administered a drug 
that blocks potassium channels. The percentage of car-
riers of genetic defects in the acquired long QT syn-
dromes is still unknown3.
Considering the occurrence of torsades de pointes 
after short-term amiodarone administration with sig-
nificant QTc prolongation and the fact that QTc in-
terval was at the upper limit of the normal value at 
discharge from the hospital, our patient probably be-
longs to the susceptible group of patients who have 
silent mutations in the function of potassium ion 
channels.
Using amiodarone as first-line therapy in the acute 
phase of disease was another important problem in the 
treatment of the patient presented. Taking into con-
sideration current guidelines for the treatment of pa-
tients with atrial fibrillation1, amiodarone should not 
have been the first-line treatment at admission in the 
case described because there were no records of ar-
rhythmia duration, size of the left atrium or possible 
thrombus presence in the left atrial auricle. In accor-
dance with the guidelines, the first-line treatment in 
this patient should have been administration of digi-
talis for rate control. Considering a relatively large 
number of similar patients admitted to ERs due to 
acute heart failure accompanied by paroxysmal atrial 
fibrillation and/or ventricular arrhythmias and wide 
amiodarone administration (often without a clear 
stronghold in the guidelines), the aim of this presenta-
tion is to warn clinicians of the possible rare side ef-
fects of such a treatment even after short-term amio-
darone administration, the necessity of immediate 
discontinuation of the drug from therapy and specific 
treatment in case of the occurrence of torsades de 
pointes, which involves administration of magnesium 
sulfate, correction of hypokalemia, lidocaine adminis-
tration11, temporary pacing, and in the most severe 
cases, electrical cardioversion and resuscitation.
In conclusion, we would like to emphasize the im-
portance of careful patient monitoring during amioda-
rone therapy, even at short-term usage, and using the 
drug in accordance with current guidelines1.
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Sažetak
TORSADES DE POINTES U BOLESNICE STARIJE ŽIVOTNE DOBI  
S PAROKSIZMALNOM ATRIJSKOM FIBRILACIJOM  
LIJEČENE KRATKOROČNOM PARENTERALNOM PRIMJENOM AMIODARONA
N. Lakušić, V. Slivnjak, N. Ciglenečki† i D. Cerovec
Jedan od lijekova koji se široko rabi u liječenju atrijske fibrilacije je amiodaron. Unatoč značajnom produljenju korigira-
nog QT intervala i usporavanju srčanog rada, amiodaron pokazuje iznimno nisku učestalost pro-aritmičkih događaja i <1,0% 
učestalosti torsades de pointes, uglavnom nakon dugotrajne uporabe. U radu je prikazan slučaj 80-godišnje žene s paroksizmal-
nom atrijskom fibrilacijom praćenom akutnim zatajenjem srca liječenom kratkotrajnom parenteralnom primjenom amioda-
rona i razvojem torsades de pointes.
Ključne riječi: Torsades de pointes; Amiodaron; Atrijska fibrilacija; Bradikardija; Prikazi slučaja
